Research programme: MC 305904 anti-fungals - Essential Therapeutics
Alternative Names: MC 305904 antifungals research programme - Essential Therapeutics; Tubulin polymerisation inhibitors research programme - Essential TherapeuticsLatest Information Update: 04 Oct 2004
At a glance
- Originator Essential Therapeutics [CEASED]
- Class
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 04 Oct 2004 Essential Therapeutics has closed down
- 04 Oct 2004 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 09 Jan 2002 Preclinical development for Mycoses in USA (Unknown route)